Kelun and Merck Lung Cancer Combo Shows Improved Survival in China Trial

A combination therapy for lung cancer developed by Kelun and Merck demonstrated improved survival rates in a late-stage clinical trial conducted in China.

Post Share

Sources

Showing 0 of 1 sources

No articles available in your preferred languages.

1 article available in other languages below.

ReutersSpanish99d ago

Kelun, Merck's lung cancer combo improves survival in late-stage China trial - Reuters

Kelun, Merck's lung cancer combo improves survival in late-stage China trial Reuters

Read full article →

PERSPECTA

PERSPECTA

Kelun and Merck Lung Cancer Combo Shows Improved Survival in China Trial

Sources

Kelun, Merck's lung cancer combo improves survival in late-stage China trial - Reuters

Related Stories

India’s GST Council Convenes After Yearlong Hiatus

HDFC Bank CEO Sashidhar Jagdishan to Retire in October

Airbus Seeks Sale of U.S. Space Unit to Bolster European Satellite Alliance

Fed Chair Warsh Signals Potential Rate Hikes Amid Stubborn Inflation

PERSPECTA